Lomerizine dihydrochloride

• Catalog No.: L6295
• CAS Number: 101477-54-7
• M. F.: C27H32Cl2F2N2O3
• M. W.: 541.4573864
• Purity: ≥98% (HPLC)

SYNONYMS

• IUPAC name: 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine dihydrochloride
• IUPAC Traditional name: lomerizine dihydrochloride
• Synonyms: 1-[Bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine dihydrochloride

DATABASE IDS

• MDL Number: MFCD01703867
• CAS Number: 101477-54-7

PROPERTIES

• Empirical Formula (Hill Notation): C27H30F2N2O3·2HCl
• Purity: ≥98% (HPLC)
• Apperance: white to tan powder
• Solubility: DMSO: ≥30 mg/mL
• GHS Signal Word: Warning
• GHS Hazard statements: H302-H410
• European Hazard Symbols: Harmful (Xn)
• European Hazard Symbols: Nature polluting (N)
• GHS Precautionary statements: P273-P501
• Risk Statements: 22-50
• RTECS: TK9189000
• Safety Statements: 61
• Storage Temperature: 2-8°C
• German water hazard class: 3

DETAILS

Description (English)

Biochem/physiol Actions
Lomerizine dihydrochloride is a voltage-dependent calcium channel blocker and selective cerebral vasodilator. It is one of the most selective calcium channel blockers for the CNS and cerebral arteries. It has been reported to inhibit both T-type and L-type Ca2+ currents in rat hippocampal CA1 pyramidal neurons, to prevent glutamate-induced neurotoxicity in rat hippocampal primary cell cultures, and to exhibit protective effects in animal models of migraine, ischemia and hypoxia. In Japan, lomerizine has been used as the first-line prophylactic drug for migraines.

Description (简体中文)

Biochem/physiol Actions
Lomerizine dihydrochloride is a voltage-dependent calcium channel blocker and selective cerebral vasodilator. It is one of the most selective calcium channel blockers for the CNS and cerebral arteries. It has been reported to inhibit both T-type and L-type Ca2+ currents in rat hippocampal CA1 pyramidal neurons, to prevent glutamate-induced neurotoxicity in rat hippocampal primary cell cultures, and to exhibit protective effects in animal models of migraine, ischemia and hypoxia. In Japan, lomerizine has been used as the first-line prophylactic drug for migraines.